Breaking News Instant updates and real-time market news.

GSK

GlaxoSmithKline

$41.43

-0.06 (-0.14%)

, QURE

uniQure

$7.34

0.14 (1.94%)

04:55
10/21/16
10/21
04:55
10/21/16
04:55

European Society for Gene and Cell Therapy to hold a conference

ESGCT 2016: Stem Cell & Gene Therapy Congress is being held in Florence, Italy on October 18-21.

GSK

GlaxoSmithKline

$41.43

-0.06 (-0.14%)

QURE

uniQure

$7.34

0.14 (1.94%)

SNE

Sony

$32.72

-0.19 (-0.58%)

ABEO

Abeona Therapeutics

$8.70

0.94 (12.11%)

SGMO

Sangamo

$3.85

0.25 (6.94%)

  • 22

    Oct

  • 26

    Oct

  • 26

    Oct

  • 06

    Nov

  • 14

    Nov

  • 29

    Nov

GSK GlaxoSmithKline
$41.43

-0.06 (-0.14%)

09/23/16
PIPR
09/23/16
INITIATION
PIPR
Overweight
GlaxoSmithKline initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Richard Purkiss started GlaxoSmithKline with an Overweight rating and GBP 20 price target. The company's growth is defensive and its risks are declining, Purkiss tells investors in a research note.
10/03/16
RBCM
10/03/16
NO CHANGE
Target $95
RBCM
Outperform
Gilead HIV franchise could see risk from competitor data, says RBC Capital
RBC Capital analyst Michael Yee said his conversations with doctors leads him to think two dolutegravir HIV "doublet" studies being conducted by GlaxoSmithKline (GSK) and ViiV Healthcare - Glaxo's joint venture with Pfizer (PFE) and Shionogi - are likely to work and present an underappreciated risk to Gilead's (GILD) HIV franchise. Talks with investors lead Yee to believe few are even aware of this risk and that the consensus view is underestimating the probability these non-inferiority trials will work. Arguing that the consensus view should factor in more conservative assumptions for Gilead's HIV business post 2018 due to this risk, Yee cut his price target on Gilead to $95 from $105, but keeps an Outperform rating on the shares.
10/06/16
PIPR
10/06/16
NO CHANGE
Target $46
PIPR
Overweight
Piper thinks Alnylam failure is positive for Ionis
Piper Jaffay analyst Joshua Schimmer thinks Alnylam Pharmaceuticals' (ALNY) "abrupt halt" of revusiran for TTR cardiomyopathy is likely a positive for Ionis Pharmaceuticals' (IONS) transthyretin program. The move "knocks out a competitive drug" while Ionis and GlaxoSmithKline (GSK) remain on their previously indicated timeline, Schimmer tells investors in a research note. The analyst at this point believes Alnylam's setback will be limited to revusiran and not read-through to other Gal-Nac programs or other TTR cardiomyopathy or polyneuropathy programs. He keeps an Overweight rating on Ionis with a $46 price target,
09/23/16
09/23/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Morgan Stanley analyst Brian Nowak initiated Activision Blizzard (ATVI) and Electronic Arts (EA), both with Overweight ratings. The analyst is bullish on the digital gaming shift away from "units sold" to a business model based on users, engagement, and digital monetization. He sees digital in-game offerings resulting in recurring and growth user bases, increased per-game engagement, and further monetization opportunities. 2. AstraZeneca (AZN) and GlaxoSmithKline (GSK) both initiated with Overweight ratings by Piper Jaffray analyst Richard Purkiss. 3. Achillion (ACHN) initiated with an Outperform by Wedbush analyst Heather Behanna, who set a $13 price target on the shares. 4. Sysco (SYY) initiated with an Underweight at Barclays and $48 price target by analyst Karen Short. 5. Five Below (FIVE), Dollar Tree (DLTR) and Dollar General (DG) all initiated with Equal Weight ratings by Barclays analyst Karen Short. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
QURE uniQure
$7.34

0.14 (1.94%)

08/04/16
HCWC
08/04/16
INITIATION
Target $21
HCWC
Buy
uniQure assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Shaunak Deepak assumed coverage of uniQure with a Buy rating and $21 price target.
08/04/16
08/04/16
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. LendingClub (LC) initiated with a Perform at Oppenheimer. 2. uniQure (QURE) assumed with a Buy at H.C. Wainwright. 3. Sunworks (SUNW) initiated with a Buy at Chardan. 4. CSX ( CSX), Canadian Pacific (CP), Norfolk Southern (NSC), and Union Pacific (UNP) initiated with a Hold, and Kansas City Southern (KSU) initiated with a Buy at Loop Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/26/16
JANY
07/26/16
NO CHANGE
Target $26
JANY
Buy
uniQure fair value estimate lowered to $26 from $40 at Janney Capital
Janney Capital analyst Debjit Chattopadhyay lowered his fair value estimate for uniQure to $26 from $40 on valuation. The analyst notes that uniQure's stock has been trading at levels suggesting not only its Hemophilia B program, but also the remainder of the pipeline is worth zero. However, he expects compelling risk/reward ahead of "significant" pipeline news over the next three quarters. Chattopadhyay reiterates a Buy rating on the shares.
06/15/16
WBTH
06/15/16
NO CHANGE
Target $35
WBTH
Buy
uniQure price target lowered to $35 from $60 at WallachBeth
WallachBeth analyst Caroline Palomeque cut her price target for uniQure to $35 after the company hosted a conference call to discuss data from its Phase I/II trial of AMT-060, its gene therapy treatment for Hemophilia B. The five-patient low-dose cohort showed that four patients improved their level of FIX activity at a mean of 5.4% of normal and that this was sustained at six months, Palomeque tells investors in a research note. She views the data as encouraging. The analyst's lowered price target reflects "overall market conditions including a contraction in the Biotech sector since 1/2016." Palomeque has a Buy rating on uniQure.
SNE Sony
$32.72

-0.19 (-0.58%)

09/09/16
PIPR
09/09/16
NO CHANGE
PIPR
August NPD video game software sales rose 1%, says Piper Jaffray
Piper Jaffray analyst Michael Olson says August NPD video game software sales were up 1% year-over-year, driven by Sony (SNE) publishing No Man's Sky and Electronic Arts' (EA) Madden NFL 17. The data are most positive for Activision Blizzard (ATVI), which continued to benefit from sell-through of incremental title Overwatch, Olson tells investors in a research note. He believes the monthly numbers are largely irrelevant for Take-Two (TTWO), since NBA 2K17 is due out in September, and GameStop (GME), since the company announced October quarter guidance at the end of August.
07/06/16
07/06/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. TASER (TASR) upgraded to Buy from Neutral at CL King with analyst George Godfrey citing strong organic growth, a leading position in body cameras, low international market exposure, accelerating earnings growth and margin expansion, and weapons segment opportunity growth. 2. Sony (SNE) upgraded to Buy from Hold at Deutsche Bank with analyst Hiroshi Taguchi saying the company's shipment growth will likely exceed expectations. 3. U.S. Steel (X) upgraded to Hold from Sell at Deutsche Bank with analyst Jorge Beristain citing his firm's improved steel price outlook as well as the company's' balance sheet refinancing. 4. SunPower (SPWR) upgraded to Buy from Neutral at UBS with Julien Dumoulin-Smith citing valuation, a strong technology track record and product development, early indications that utility scale margins are proving more intact versus expectations, and a solid balance sheet. 5. Royal Gold (RGLD) upgraded to Outperform from Market Perform at Raymond James and to Buy from Neutral at Dundee. Raymond James analyst Phil Russo upgraded Royal Gold to Outperform and increased his price target to $85 from $72 following amended terms at Mt Milligan with new operator Centerra Gold. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/24/16
STFL
08/24/16
NO CHANGE
STFL
Ambarella Q2 revenue guidance could beat expectations, says Stifel
Stifel analyst Kevin Cassidy says he is "cautiously optimistic" that Ambarella's (AMBA) Q2 revenue guidance will come in above expectations. The company was worried about whether Sony (SNE) would be able to meet demand for its sensors used in high end surveillance cameras, but recent checks show that it was able to do so, the analyst stated. Additionally, Ambarella's Q3 guidance should project year-over-year growth, given GoPro's (GPRO) initial Hero 5 builds, according to Cassidy. He keeps an $86 price target and Buy rating on Ambarella.
08/18/16
PIPR
08/18/16
NO CHANGE
Target $41
PIPR
Overweight
Piper Jaffray bullish on GameStop ahead of quarterly results
With GameStop (GME) scheduled to report results next week, Piper Jaffray analyst Michael Olson sees potential for slight July quarter upside driven by May launches of Sony's (SNE) Uncharted 4 and Activision's (ATVI) Overwatch. Further, the analyst expects largely unchanged fiscal year guide, and anticipates improving software growth in the second half of the year, driven by easier comps and a next-generation console footprint that he believes is over 60M units. Olson reiterates an Overweight rating and $41 price target on GameStop's shares.
ABEO Abeona Therapeutics
$8.70

0.94 (12.11%)

09/29/16
MAXM
09/29/16
NO CHANGE
Target $14
MAXM
Buy
Abeona Therapeutics price target raised to $14 from $8 at Maxim
Maxim analyst Jason McCarthy raised Abeona's price target to $14 from $8 saying he expects multiple data points across several gene therapy programs to potentially push shares higher. The analyst said clinical development is underway in Abeona's Sanfilippo with positive data in two patients so far, and data from more patients are expected this fall. The company is also advancing a second Sanfilippo gene therapy, ABO-101, into the clinic later this year. Also, Abeona has brought on board a more advanced gene therapy from Stanford University, EB-101, to treat a rare skin disease which demonstrated positive data in five patients and has advanced to phase II, McCarthy wrote.
09/21/16
MAXM
09/21/16
NO CHANGE
Target $8
MAXM
Buy
Abeona Therapeutics price target raised to $8 from $6 at Maxim
Maxim raised Buy rated Abeona's price target to $8 from $6 following news the company has licensed a next-generation AAV gene therapy platform from the University of North Carolina that may make gene therapy available to patients with CNS disorders who have immune responses against natural AAV vectors used in first-generation AAV gene therapies currently in development.
09/07/16
CANT
09/07/16
INITIATION
Target $21
CANT
Buy
Abeona Therapeutics initiated with a Buy at Cantor
Cantor initiated Abeona Therapeutics with a Buy and $21 price target.
12/16/15
12/16/15
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Abeona Therapeutics (ABEO) initiated with a Buy at Maxim... Accelerate Diagnostics (AXDX) initiated with an Overweight at Piper Jaffray... Aetna (AET) initiated with a Neutral at Credit Suisse... Agenus (AGEN) initiated with a Buy at Jefferies... Apple Hospitality REIT (APLE) initiated with a Buy at Canaccord... Brunswick (BC) initiated with an Overweight at JPMorgan... Carlisle (CSL) initiated with a Buy at Wunderlich... Castlight Health (CSLT) initiated with a Buy at Topeka... Centene (CNC) initiated with an Outperform at Credit Suisse... ConAgra (CAG) initiated with a Buy at Jefferies... Dean Foods (DF) initiated with a Buy at Jefferies... First Merchants (FRME) initiated with a Neutral at SunTrust... Flowers Foods (FLO) initiated with a Buy at Jefferies... Glatfelter (GLT) initiated with a Buy at Sidoti... HCA Holdings (HCA) initiated with an Outperform at Credit Suisse... Hain Celestial (HAIN) assumed with a Buy at Jefferies... Hormel Foods (HRL) initiated with a Buy at Jefferies... Humana (HUM) initiated with a Neutral at Credit Suisse... Ingredion (INGR) initiated with a Buy at Jefferies... J & J Snack Foods (JJSF) initiated with a Hold at Jefferies... J.M. Smucker (SJM) initiated with a Buy at Jefferies... Kura Oncology (KURA) initiated with a Buy at Citi... LifePoint (LPNT) initiated with an Outperform at Credit Suisse... MasterCard (MA) initiated with a Buy at UBS... Matador (MTDR) initiated with a Neutral at BofA/Merrill... McCormick (MKC) initiated with a Hold at Jefferies... Molina Healthcare (MOH) initiated with a Neutral at Credit Suisse... NetApp (NTAP) initiated with an Underperform at JMP Securities... Nimble Storage (NMBL) initiated with a Market Perform at JMP Securities... Pilgrim's Pride (PPC) initiated with a Hold at Jefferies... Pure Storage (PSTG) initiated with an Outperform at JMP Securities... Rexford Industrial (REXR) initiated with a Buy at Stifel... Rice Energy (RICE) initiated with a Hold at Deutsche Bank... Sanderson Farms (SAFM) initiated with an Underperform at Jefferies... Snyder's-Lance (LNCE) initiated with a Buy at Jefferies... SodaStream (SODA) initiated with a Hold at Jefferies... Tenet (THC) initiated with a Neutral at Credit Suisse... TreeHouse (THS) initiated with a Buy at Jefferies... Tyson Foods (TSN) initiated with a Buy at Jefferies... UnitedHealth (UNH) initiated with an Outperform at Credit Suisse... Universal Health (UHS) initiated with a Neutral at Credit Suisse... Varonis (VRNS) initiated with a Buy at Lake Street... Visa (V) initiated with a Buy at UBS... WellCare (WCG) initiated with an Underperform at Credit Suisse... WhiteWave (WWAV) initiated with a Buy at Jefferies... aTyr Pharma (LIFE) initiated with a Neutral at Citi.
SGMO Sangamo
$3.85

0.25 (6.94%)

10/19/16
PIPR
10/19/16
DOWNGRADE
PIPR
Neutral
Sangamo downgraded to Neutral from Overweight at Piper Jaffray
09/06/16
WELS
09/06/16
NO CHANGE
WELS
Outperform
Wells calls Sangamo an 'attractive new investment opportunity'
After the FDA granted orphan drug designation to its Factor IX gene-editing product candidate, SB-FIX, as a treatment for hemophilia B, Wells Fargo analyst Jim Birchenough calls Sangamo BioSciences an "attractive new investment opportunity." Along with validating a commercial opportunity in hemophilia, SB-FIX could provide "even more valuable validation of targeting and coopting the albumin gene locus for gene insertion that may apply to a wide variety of genetic diseases," Birchenough tells investors in a research note. He keeps an Outperform rating on the shares.
08/04/16
JANY
08/04/16
DOWNGRADE
JANY
Neutral
Sangamo downgraded to Neutral from Buy at Janney Capital
03/07/16
JANY
03/07/16
NO CHANGE
Target $15
JANY
Buy
Sangamo data support expectations for IVPRP efficacy, says Janney Capital
Janney Capital analyst Roy Buchanan says that updated mouse data for Sangamo's in vivo protein replacement platform, or IVPRP, for treating MPS I and II continue to support expectations for efficacy and that the brain data is encouraging and adds additional support. The analyst notes, however, that he hasn't increased his probability of success for the program on this data, as much of it had been presented previously. Buchanan keeps a Buy rating and $15 fair value estimate on Sangamo shares.

TODAY'S FREE FLY STORIES

$NYE

NYSE Market Internals

10:16
04/28/17
04/28
10:16
04/28/17
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLDR

Cloudera

10:15
04/28/17
04/28
10:15
04/28/17
10:15
Syndicate
Breaking Syndicate news story on Cloudera »

Cloudera IPO indicated to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

10:15
04/28/17
04/28
10:15
04/28/17
10:15
General news
FX Action: The dollar »

FX Action: The dollar was…

ANTM

Anthem

$177.90

-0.4 (-0.22%)

, CI

Cigna

$155.93

-0.28 (-0.18%)

10:13
04/28/17
04/28
10:13
04/28/17
10:13
Periodicals
Breaking Periodicals news story on Anthem, Cigna »

Appeals court upholds…

ANTM

Anthem

$177.90

-0.4 (-0.22%)

CI

Cigna

$155.93

-0.28 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    May

  • 18

    May

RDUS

Radius Health

$38.72

-0.5 (-1.27%)

10:12
04/28/17
04/28
10:12
04/28/17
10:12
Hot Stocks
FDA website shows approval of Radius Health's Tymlos »

Shares of Radius Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 03

    May

  • 02

    Jun

  • 30

    Jun

WDC

Western Digital

$85.71

1.1 (1.30%)

10:11
04/28/17
04/28
10:11
04/28/17
10:11
Recommendations
Western Digital analyst commentary  »

Western Digital price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$10.50

0.14 (1.35%)

10:11
04/28/17
04/28
10:11
04/28/17
10:11
Options
Opening action in VIX August calls »

Opening action in VIX…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLDR

Cloudera

10:10
04/28/17
04/28
10:10
04/28/17
10:10
Syndicate
Breaking Syndicate news story on Cloudera »

Cloudera IPO indicated to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

NVS

Novartis

$76.70

-0.36 (-0.47%)

10:10
04/28/17
04/28
10:10
04/28/17
10:10
Hot Stocks
FDA approves Novartis' combination treatment for AML »

The U.S. Food and Drug…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 05

    May

  • 07

    May

  • 06

    Jun

  • 26

    Jun

SWKS

Skyworks

$104.20

1.23 (1.19%)

, SSNLF

Samsung

10:09
04/28/17
04/28
10:09
04/28/17
10:09
Recommendations
Skyworks, Samsung analyst commentary  »

Skyworks price target…

SWKS

Skyworks

$104.20

1.23 (1.19%)

SSNLF

Samsung

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

  • 30

    May

RDUS

Radius Health

$38.72

-0.5 (-1.27%)

10:07
04/28/17
04/28
10:07
04/28/17
10:07
Hot Stocks
Radius Health jumps after FDA posts approval of Tymlos 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 03

    May

  • 02

    Jun

  • 30

    Jun

ORLY

O'Reilly Automotive

$257.19

-7.88 (-2.97%)

10:02
04/28/17
04/28
10:02
04/28/17
10:02
Recommendations
O'Reilly Automotive analyst commentary  »

O'Reilly Automotive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jun

MHK

Mohawk

$229.91

-8.97 (-3.76%)

10:01
04/28/17
04/28
10:01
04/28/17
10:01
Technical Analysis
Mohawk testing uptrend support line following earnings »

The shares were last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

10:01
04/28/17
04/28
10:01
04/28/17
10:01
General news
Consumer Sentiment Index data reported »

April Consumer Sentiment…

CL

Colgate-Palmolive

$72.10

-1.2 (-1.64%)

10:01
04/28/17
04/28
10:01
04/28/17
10:01
Options
Call buyer in Colgate as shares fall on earnings »

Call buyer in Colgate as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 31

    May

EEX

Emerald Expositions Events

10:00
04/28/17
04/28
10:00
04/28/17
10:00
Syndicate
Breaking Syndicate news story on Emerald Expositions Events »

Emerald Expositions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

IVC

Invacare

$14.85

1.6 (12.08%)

09:59
04/28/17
04/28
09:59
04/28/17
09:59
Upgrade
Invacare rating change  »

Invacare upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 18

    May

CVNA

Carvana

09:58
04/28/17
04/28
09:58
04/28/17
09:58
Syndicate
Breaking Syndicate news story on Carvana »

Carvana opens at $13.50,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

EFX

Equifax

$134.84

-1.35 (-0.99%)

09:56
04/28/17
04/28
09:56
04/28/17
09:56
Downgrade
Equifax rating change  »

Equifax downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 04

    May

EEX

Emerald Expositions Events

09:55
04/28/17
04/28
09:55
04/28/17
09:55
Syndicate
Breaking Syndicate news story on Emerald Expositions Events »

Emerald Expositions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

09:55
04/28/17
04/28
09:55
04/28/17
09:55
General news
U.S. Chicago PMI increased 0.6 points to 58.3 in April »

U.S. Chicago PMI…

CSGP

CoStar Group

$236.71

17.35 (7.91%)

09:53
04/28/17
04/28
09:53
04/28/17
09:53
Recommendations
CoStar Group analyst commentary  »

CoStar Group price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 21

    Jun

  • 22

    Jun

  • 22

    Jun

BOKF

BOK Financial

$85.04

-0.42 (-0.49%)

09:51
04/28/17
04/28
09:51
04/28/17
09:51
Upgrade
BOK Financial rating change  »

BOK Financial upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

OCLR

Oclaro

$7.93

0.01 (0.13%)

09:51
04/28/17
04/28
09:51
04/28/17
09:51
Recommendations
Oclaro analyst commentary  »

Oclaro estimates lowered …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 30

    May

BSX

Boston Scientific

$26.16

-0.02 (-0.08%)

09:51
04/28/17
04/28
09:51
04/28/17
09:51
Options
Active trading in Boston Scientific short-term calls »

Active trading in Boston…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 07

    Jun

  • 27

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.